Form 4: Bristol-Myers Squibb EVP Acquires 22,568 RSUs

Bristol-Myers Squibb's EVP, Chief Commercial Officer, Adam Lenkowsky, acquired 22,568 restricted stock units, vesting over three years.

Summary

• Adam Lenkowsky, Executive Vice President and Chief Commercial Officer of Bristol-Myers Squibb Co (BMY), reported the acquisition of 22,568 Restricted Stock Units (RSUs).
• The transaction date for this acquisition was November 3, 2025.
• Each restricted stock unit converts into one share of common stock upon vesting.
• The 22,568 restricted stock units will vest in three equal annual installments, commencing on November 3, 2026.
• The expiration date for these restricted stock units is November 3, 2028.
• Following this transaction, Adam Lenkowsky directly beneficially owns 22,568 derivative securities (Restricted Stock Units).
• Lenkowsky also beneficially owns 12,439 shares of Common Stock directly.
• Indirect beneficial ownership includes 5,772.35 shares of Common Stock through the BMS Savings and Investment Program (401k plan) and 5,723.157 shares of Common Stock indirectly by spouse.

Sentiment

Score: 7

Explanation: The acquisition of restricted stock units by a key executive indicates alignment of interests with shareholders and a commitment to the company's long-term performance, which is generally viewed positively. However, it does not reflect direct operational or financial performance.

Positives

• The acquisition of 22,568 Restricted Stock Units by a key executive, Adam Lenkowsky, aligns management's interests with long-term shareholder value creation.
• Equity-based compensation encourages executives to focus on sustained company performance.

Future Outlook

This filing is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

This Form 4 filing reports a routine executive compensation event, specifically the grant of restricted stock units. Such equity grants are a common practice across the pharmaceutical and biotechnology industries to incentivize executive performance and align their interests with long-term company success. It does not provide broader industry trend analysis.

Comparison to Industry Standards

• Executive equity compensation, such as Restricted Stock Units, is a standard practice in the pharmaceutical industry, comparable to compensation structures at companies like Pfizer, Merck, and Johnson & Johnson, which use similar mechanisms to retain talent and align executive incentives with shareholder value.

Stakeholder Impact

• Shareholders: The RSU grant aligns the executive's financial interests with the long-term performance of the company, potentially benefiting shareholders through sustained value creation.

Next Steps

• The Restricted Stock Units will vest in three equal annual installments beginning on November 3, 2026.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event (RSU grant) and does not provide sufficient new fundamental information to alter an existing investment thesis. It primarily indicates executive alignment with long-term company performance, which is a standard governance practice.

Keywords

Bristol-Myers Squibb, BMY, Adam Lenkowsky, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, SEC Form 4, Pharmaceuticals, Biopharma